Kelonia Therapeutics
Pioneering in vivo CAR-T Therapies to bring genetic medicines to the masses
Key Highlights
- Democratizing CAR-T Therapy: Kelonia’s best-in-class in vivo gene placement system (iGPS) enables the efficient delivery of genetic medicine with high tissue specificity and avoids costly and lengthy ex vivo manufacturing, burdensome lymphodepleting chemotherapy and reliance on large research hospitals
- $800M Collaboration with Astellas aims to develop universal in vivo CAR-T therapies and has potential applications in cancer and autoimmune conditions
- Key Events in 2024: IND for lead candidate KLN-1010 in multiple myeloma